Literature DB >> 1878582

Does the breakpoint within the major breakpoint cluster region (M-bcr) influence the duration of the chronic phase in chronic myeloid leukemia? An analytical comparison of current literature.

K I Mills1, P Benn, G D Birnie.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1878582

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  6 in total

1.  Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib.

Authors:  Benjamin Hanfstein; Michael Lauseker; Rüdiger Hehlmann; Susanne Saussele; Philipp Erben; Christian Dietz; Alice Fabarius; Ulrike Proetel; Susanne Schnittger; Claudia Haferlach; Stefan W Krause; Jörg Schubert; Hermann Einsele; Mathias Hänel; Jolanta Dengler; Christiane Falge; Lothar Kanz; Andreas Neubauer; Michael Kneba; Frank Stegelmann; Michael Pfreundschuh; Cornelius F Waller; Karsten Spiekermann; Gabriela M Baerlocher; Markus Pfirrmann; Joerg Hasford; Wolf-Karsten Hofmann; Andreas Hochhaus; Martin C Müller
Journal:  Haematologica       Date:  2014-05-16       Impact factor: 9.941

2.  Stromal cell-derived factor-1 chemokine gene variant in blood donors and chronic myelogenous leukemia patients.

Authors:  Carlos Eduardo Coral de Oliveira; Gabriela Gonçalves de Oliveira Cavassin; Aparecida de Lourdes Perim; Thiago Franco Nasser; Karen Brajão de Oliveira; Maria Helena Pelegrinelli Fungaro; Juliana Laino do Val Carneiro; Maria Angelica Ehara Watanabe
Journal:  J Clin Lab Anal       Date:  2007       Impact factor: 2.352

Review 3.  The molecular genetics of hematologic malignancies.

Authors:  A Bagg
Journal:  Clin Diagn Lab Immunol       Date:  1995-05

4.  Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript.

Authors:  Claire M Lucas; Robert J Harris; Athina Giannoudis; Andrea Davies; Katy Knight; Sarah J Watmough; Lihui Wang; Richard E Clark
Journal:  Haematologica       Date:  2009-08-27       Impact factor: 9.941

5.  Response to Imatinib therapy is inferior for e13a2 BCR-ABL1 transcript type in comparison to e14a2 transcript type in chronic myeloid leukaemia.

Authors:  Graeme Greenfield; Ross McMullan; Nuala Robson; Julie McGimpsey; Mark Catherwood; Mary Frances McMullin
Journal:  BMC Hematol       Date:  2019-05-02

6.  Differences in structural elements of Bcr-Abl oncoprotein isoforms in Chronic Myelogenous Leukemia.

Authors:  Abdul Hai; Nadeem A Kizilbash; Syeda Huma H Zaidi; Jamal Alruwaili; Khuram Shahzad
Journal:  Bioinformation       Date:  2014-03-19
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.